However, the role of CB2 in the progression of NAFLD has been debated: on the one hand, studies on the activation of both CB1 and CB2 receptors have shown increased lipid accumulation [46] and potentiation of hepatic steatosis [47]; on the other hand, our results with a CB2 antagonist show that CB2 activation can counteract steatosis, in line with other works [24,48,49]. The gene discussed is CNR2; the disease is fatty liver disease.